XSNX Stock Overview
A biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
NovAccess Global Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.005 |
| 52 Week High | US$0.054 |
| 52 Week Low | US$0.0011 |
| Beta | 1.82 |
| 11 Month Change | 25.00% |
| 3 Month Change | -29.38% |
| 1 Year Change | -83.33% |
| 33 Year Change | -98.89% |
| 5 Year Change | -99.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| XSNX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -44.4% | 2.4% | 0.5% |
| 1Y | -83.3% | 15.6% | 30.7% |
Return vs Industry: XSNX underperformed the US Biotechs industry which returned 18.8% over the past year.
Return vs Market: XSNX underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| XSNX volatility | |
|---|---|
| XSNX Average Weekly Movement | 78.3% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: XSNX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: XSNX's weekly volatility has increased from 50% to 78% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 3 | Dwain Morris-Irvin | www.novaccessglobal.com |
NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio.
NovAccess Global Inc. Fundamentals Summary
| XSNX fundamental statistics | |
|---|---|
| Market cap | US$309.53k |
| Earnings (TTM) | -US$1.89m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs XSNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XSNX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.89m |
| Earnings | -US$1.89m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.031 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -30.6% |
How did XSNX perform over the long term?
See historical performance and comparison